MX2012002276A - Compuestos eteres aralquil bencilicos, proceso de preparacion de los mismos, compuestos intermediarios, uso de dichos compuestos, metodo de tratamiento y/o prevencion, composicion farmaceutica y medicamento que contiene dichos compuestos. - Google Patents
Compuestos eteres aralquil bencilicos, proceso de preparacion de los mismos, compuestos intermediarios, uso de dichos compuestos, metodo de tratamiento y/o prevencion, composicion farmaceutica y medicamento que contiene dichos compuestos.Info
- Publication number
- MX2012002276A MX2012002276A MX2012002276A MX2012002276A MX2012002276A MX 2012002276 A MX2012002276 A MX 2012002276A MX 2012002276 A MX2012002276 A MX 2012002276A MX 2012002276 A MX2012002276 A MX 2012002276A MX 2012002276 A MX2012002276 A MX 2012002276A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- stands
- hydrogen
- aryl
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000003814 drug Substances 0.000 title abstract 3
- -1 Benzyl aralkyl ether compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 244000005700 microbiome Species 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000002883 imidazolyl group Chemical group 0.000 abstract 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C22/00—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom
- C07C22/02—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings
- C07C22/04—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings
- C07C22/08—Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0904249-0A BRPI0904249B1 (pt) | 2009-08-28 | 2009-08-28 | Compostos éteres aralquil benzílicos, processo de preparação dos mesmos, uso dos referidos compostos, composição farmacêutica |
| PCT/BR2010/000276 WO2011022798A1 (pt) | 2009-08-28 | 2010-08-27 | Compostos éteres aralquil benzílicos, processo de preparação dos mesmos, compostos intermediários, uso dos referidos compostos, método de tratamento e/ou prevenção, composição farmacêutica e medicamento contendo os mesmos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012002276A true MX2012002276A (es) | 2012-04-19 |
Family
ID=43627099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002276A MX2012002276A (es) | 2009-08-28 | 2010-08-27 | Compuestos eteres aralquil bencilicos, proceso de preparacion de los mismos, compuestos intermediarios, uso de dichos compuestos, metodo de tratamiento y/o prevencion, composicion farmaceutica y medicamento que contiene dichos compuestos. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8975289B2 (enExample) |
| EP (1) | EP2471781B1 (enExample) |
| JP (1) | JP5718334B2 (enExample) |
| KR (1) | KR101765752B1 (enExample) |
| CN (1) | CN102625800A (enExample) |
| AR (1) | AR078115A1 (enExample) |
| AU (1) | AU2010286266B2 (enExample) |
| BR (1) | BRPI0904249B1 (enExample) |
| CA (1) | CA2771044C (enExample) |
| CL (1) | CL2012000463A1 (enExample) |
| DK (1) | DK2471781T3 (enExample) |
| ES (1) | ES2606168T3 (enExample) |
| HU (1) | HUE032199T2 (enExample) |
| IL (1) | IL218044A (enExample) |
| IN (1) | IN2012DN00611A (enExample) |
| MX (1) | MX2012002276A (enExample) |
| PE (1) | PE20120921A1 (enExample) |
| PL (1) | PL2471781T3 (enExample) |
| PT (1) | PT2471781T (enExample) |
| RU (1) | RU2548009C2 (enExample) |
| SG (1) | SG178298A1 (enExample) |
| UA (1) | UA108479C2 (enExample) |
| WO (1) | WO2011022798A1 (enExample) |
| ZA (1) | ZA201201442B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579829B (zh) * | 2012-03-06 | 2013-09-18 | 康莉 | 一种治疗牛放线菌病的中药组合物及其制备方法 |
| CN104016837B (zh) * | 2014-05-26 | 2016-08-24 | 武汉有机实业有限公司 | 4,4’-二甲基二苄基醚的制备方法 |
| RU2603622C1 (ru) * | 2015-06-25 | 2016-11-27 | Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" | Комплексный метод лечения тейлериоза мелкого рогатого скота |
| CN108047147A (zh) * | 2017-12-08 | 2018-05-18 | 长江大学 | 一类三唑类化合物以及作为杀菌剂的用途 |
| KR101983575B1 (ko) * | 2017-12-21 | 2019-06-03 | 대한민국 | 신균주 세라토바시디움 속 js1289 및 이의 용도 |
| CN114222573A (zh) * | 2019-08-16 | 2022-03-22 | 普度研究基金会 | 蛋白酶体核心颗粒的小分子刺激物 |
| JP2023057423A (ja) * | 2021-10-11 | 2023-04-21 | 国立大学法人 熊本大学 | ムコール症治療薬 |
| CN117945867B (zh) * | 2024-01-12 | 2026-06-12 | 海南师范大学 | 一种抗菌活性苄基苯醚类衍生物及其制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1170188A (en) | 1967-09-15 | 1969-11-12 | Bayer Ag | N-trityl-imidazoles and salts and uses thereof |
| SU557755A3 (ru) * | 1968-08-19 | 1977-05-05 | Янссен Фармасьютика Н.В. (Фирма) | Способ получени производных имидазола |
| DE2333354C2 (de) * | 1973-06-30 | 1983-12-15 | Bayer Ag, 5090 Leverkusen | 2-Aryloxy-2-(imidazol-1-yl)-äthanole sowie deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als Fungizide |
| GB1475271A (en) | 1975-04-30 | 1977-06-01 | Pfizer Ltd | 1-aryl-2-1-imidazolyl-alkyl ethers and thioethers and their use as antifungal agents |
| DE2556319A1 (de) * | 1975-12-13 | 1977-06-23 | Basf Ag | Substituierte triazol-aether |
| US4144346A (en) | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
| US4218458A (en) | 1978-06-23 | 1980-08-19 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4277475A (en) * | 1979-01-11 | 1981-07-07 | Syntex (U.S.A.) Inc. | Contraceptive methods employing 1-substituted imidazole derivatives |
| BE885957A (nl) | 1980-10-31 | 1981-04-30 | Amylum Graanderivaten Raff | Inrichting voor de continue bereiding van zetmeellijm |
| US4368186A (en) * | 1981-05-07 | 1983-01-11 | Syntex (U.S.A.) Inc. | Methods and compositions for intravaginal contraception |
| DE3314738A1 (de) * | 1983-04-23 | 1984-10-25 | Bayer Ag, 5090 Leverkusen | Azolylethyl-benzyl-ether-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide |
| US5278175A (en) | 1990-02-02 | 1994-01-11 | Pfizer Inc. | Triazole antifungal agents |
| JP2875140B2 (ja) * | 1993-08-16 | 1999-03-24 | 明治製菓株式会社 | 抗ｍｒｓａ組成物 |
| US5461068A (en) | 1993-09-29 | 1995-10-24 | Corwood Laboratories, Inc. | Imidazole derivative tincture and method of manufacture |
| US5750147A (en) | 1995-06-07 | 1998-05-12 | Emisphere Technologies, Inc. | Method of solubilizing and encapsulating itraconazole |
| WO2006081327A2 (en) * | 2005-01-25 | 2006-08-03 | University Of Vermont And State Agricultural College | Small molecules that reduce fungal growth |
| US20080233053A1 (en) * | 2005-02-07 | 2008-09-25 | Pharmalight Inc. | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients |
| GB0714226D0 (en) * | 2007-07-20 | 2007-08-29 | Therapeutics Ltd E | anti-bacterial combination therapy |
| GB0724996D0 (en) * | 2007-12-21 | 2008-01-30 | Therapeutics Ltd E | Antibacterial combination therapy for the treatment of gram positive bacterial infections |
| GB0813211D0 (en) * | 2008-07-18 | 2008-08-27 | E Therapeutics Plc | Antibacterial combination therapy for the treatment of gram positive bacterial infections |
| CA2735460A1 (en) * | 2008-08-29 | 2010-03-04 | The Uab Research Foundation | Novel anti-arrhythmia agent |
-
2009
- 2009-08-28 BR BRPI0904249-0A patent/BRPI0904249B1/pt active IP Right Grant
-
2010
- 2010-08-27 IN IN611DEN2012 patent/IN2012DN00611A/en unknown
- 2010-08-27 US US13/389,741 patent/US8975289B2/en active Active
- 2010-08-27 KR KR1020127007355A patent/KR101765752B1/ko active Active
- 2010-08-27 MX MX2012002276A patent/MX2012002276A/es active IP Right Grant
- 2010-08-27 ES ES10811042.0T patent/ES2606168T3/es active Active
- 2010-08-27 HU HUE10811042A patent/HUE032199T2/en unknown
- 2010-08-27 CN CN201080038108XA patent/CN102625800A/zh active Pending
- 2010-08-27 JP JP2012525824A patent/JP5718334B2/ja active Active
- 2010-08-27 DK DK10811042.0T patent/DK2471781T3/da active
- 2010-08-27 PE PE2012000254A patent/PE20120921A1/es active IP Right Grant
- 2010-08-27 WO PCT/BR2010/000276 patent/WO2011022798A1/pt not_active Ceased
- 2010-08-27 EP EP10811042.0A patent/EP2471781B1/en active Active
- 2010-08-27 PL PL10811042T patent/PL2471781T3/pl unknown
- 2010-08-27 CA CA2771044A patent/CA2771044C/en active Active
- 2010-08-27 UA UAA201203947A patent/UA108479C2/ru unknown
- 2010-08-27 AU AU2010286266A patent/AU2010286266B2/en not_active Ceased
- 2010-08-27 RU RU2012110925/04A patent/RU2548009C2/ru active
- 2010-08-27 SG SG2012008488A patent/SG178298A1/en unknown
- 2010-08-27 PT PT108110420T patent/PT2471781T/pt unknown
- 2010-08-30 AR ARP100103171A patent/AR078115A1/es active IP Right Grant
-
2012
- 2012-02-09 IL IL218044A patent/IL218044A/en active IP Right Grant
- 2012-02-23 CL CL2012000463A patent/CL2012000463A1/es unknown
- 2012-02-27 ZA ZA2012/01442A patent/ZA201201442B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2471781T (pt) | 2016-12-15 |
| PL2471781T3 (pl) | 2017-08-31 |
| AU2010286266B2 (en) | 2015-02-12 |
| AR078115A1 (es) | 2011-10-12 |
| HUE032199T2 (en) | 2017-08-28 |
| AU2010286266A1 (en) | 2012-04-05 |
| KR20120050490A (ko) | 2012-05-18 |
| RU2012110925A (ru) | 2013-10-10 |
| DK2471781T3 (da) | 2017-01-02 |
| EP2471781A1 (en) | 2012-07-04 |
| KR101765752B1 (ko) | 2017-08-07 |
| IN2012DN00611A (enExample) | 2015-06-12 |
| EP2471781B1 (en) | 2016-09-07 |
| JP5718334B2 (ja) | 2015-05-13 |
| US8975289B2 (en) | 2015-03-10 |
| IL218044A0 (en) | 2012-04-30 |
| CL2012000463A1 (es) | 2012-09-21 |
| US20120196908A1 (en) | 2012-08-02 |
| CA2771044A1 (en) | 2011-03-03 |
| IL218044A (en) | 2017-02-28 |
| BRPI0904249B1 (pt) | 2018-03-06 |
| SG178298A1 (en) | 2012-03-29 |
| UA108479C2 (en) | 2015-05-12 |
| EP2471781A4 (en) | 2013-01-23 |
| ZA201201442B (en) | 2012-10-31 |
| CA2771044C (en) | 2017-07-04 |
| CN102625800A (zh) | 2012-08-01 |
| RU2548009C2 (ru) | 2015-04-10 |
| WO2011022798A1 (pt) | 2011-03-03 |
| ES2606168T3 (es) | 2017-03-23 |
| BRPI0904249A2 (pt) | 2011-05-17 |
| PE20120921A1 (es) | 2012-08-01 |
| JP2013503111A (ja) | 2013-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000642A (es) | Compuestos macrociclicos para el tratamiento de cancer | |
| UA108479C2 (en) | Benzyl aralkyl ether compounds, their preparation, use of such compounds and methods for treating and / or preventing diseases | |
| TW200833675A (en) | Nicotinamide derivatives | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| MXPA05011670A (es) | Derivados de azetidincarboxamida y su uso en el tratamiento de trastornos mediados por el receptor cb1. | |
| MX2008010187A (es) | Tratamiento de distrofia muscular de duchenne. | |
| WO2008012635A3 (en) | Amine derivatives useful as anticancer agents | |
| NO20062135L (no) | Fenylderivater som PPAR-agonister | |
| YU95102A (sh) | Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija | |
| MY142807A (en) | Benzimidazole derivative and use thereof. | |
| NO20076196L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
| MX2023010909A (es) | Derivados de purina como agentes anticancerigenos. | |
| DE602008001725D1 (de) | 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus | |
| MX2011013648A (es) | Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos. | |
| NO20093275L (no) | 1,3-Dihydroimidazol-2-thione derivater som inhibitorer av dopamin-beta-hydroksylase | |
| MX2023015139A (es) | Inhibidores de mutacion de her2. | |
| MX2025010357A (es) | Degradador de irak4, y uso del mismo | |
| TW200745066A (en) | Novel PTP1B inhibitors | |
| TW200942529A (en) | Pyrrolidinyl derivatives and uses thereof | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| MX2009012518A (es) | Derivados de piperidina 4,4-disubstituidos. | |
| TW200716527A (en) | Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives | |
| MX2009003728A (es) | Nuevos derivados de alcaloides de isocarbostirilo que tienen actividades anti-proliferativas y anti-migratorias. | |
| WO2008106125A3 (en) | Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists | |
| TNSN02096A1 (en) | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |